Home

Athena Countouriotis

CIK 1571469 · President & CEO · last filed 2026-06-18

Athena Countouriotis is a President & CEO who has filed 45 SEC Form 4 insider transactions across 8 companies since 2013. The most recent filing, for IOVA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$7.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.31M

Companies

8

Total Filings

45

Lifetime Open-Market Net

-$7.13M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IOVA Director — $4.70 — $0 9 2026-06-18
BMRN Director 21,040 $62.07 $1.31M $0 4 2026-06-04
PASG Director 945 $4.57 $4.3K $309.9K 9 2026-05-21
Turning Point Therapeutics, Inc. (TPTX) Delisted President & CEO 0 $76.01 $0 -$7.44M 8 2022-08-17
Cardiff Oncology, Inc. (TROV) Delisted Director — — — $0 2 2019-06-24
Adverum Biotechnologies, Inc. (ADVM) Delisted SVP, Chief Medical Officer 15,000 $4.36 $65.4K $0 2 2018-02-20
HALOZYME THERAPEUTICS, INC. (HTI) Delisted SVP and Chief Medical Officer 45,977 — — $0 8 2017-02-24
AMBIT BIOSCIENCES CORP (AMBI) Delisted Chief Medical Officer — $0.54 — $0 3 2014-11-12

Recent Filings

45 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 IOVA Grant (A) — $0 EDGAR
2026-06-04 BMRN Grant (A) +7,490 $0 EDGAR
2026-05-21 PASG Grant (A) — $0 EDGAR
2025-06-17 IOVA Grant (A) — $0 EDGAR
2025-05-30 PASG Grant (A) — $0 EDGAR
2025-05-22 BMRN Grant (A) +6,650 $0 EDGAR
2024-06-13 IOVA Grant (A) — $0 EDGAR
2024-05-23 BMRN Grant (A) +4,720 $0 EDGAR
2024-05-23 PASG Grant (A) — $0 EDGAR
2024-03-05 IOVA Grant (A) — $0 EDGAR
Showing 1–10 of 45
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.